Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Kura Oncology, Inc. (NASDAQ:KURA) has received a consensus rating of “Moderate Buy” from the eleven analysts that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $27.38.

Several analysts have recently commented on KURA shares. HC Wainwright upped their price objective on shares of Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, November 21st. Stifel Nicolaus cut Kura Oncology from a “buy” rating to a “hold” rating and decreased their price objective for the company from $26.00 to $19.00 in a report on Monday, October 14th. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research note on Monday, December 9th. JMP Securities reiterated a “market outperform” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Tuesday, November 19th. Finally, UBS Group started coverage on shares of Kura Oncology in a research note on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective on the stock.

Kura Oncology Trading Up 4.5 %

Shares of Kura Oncology stock opened at $8.21 on Friday. The firm’s 50 day simple moving average is $9.88 and its two-hundred day simple moving average is $16.09. The firm has a market capitalization of $638.41 million, a price-to-earnings ratio of -3.48 and a beta of 0.81. Kura Oncology has a 12-month low of $6.98 and a 12-month high of $24.17. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.01. During the same period last year, the company earned ($0.50) earnings per share. Analysts predict that Kura Oncology will post -2.44 EPS for the current year.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds have recently modified their holdings of KURA. Suvretta Capital Management LLC grew its stake in Kura Oncology by 8.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock valued at $149,535,000 after acquiring an additional 583,155 shares in the last quarter. Armistice Capital LLC boosted its holdings in Kura Oncology by 14.7% in the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after purchasing an additional 302,000 shares during the last quarter. Geode Capital Management LLC grew its position in Kura Oncology by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock worth $34,798,000 after acquiring an additional 41,535 shares during the period. Franklin Resources Inc. grew its holdings in shares of Kura Oncology by 1.5% during the 3rd quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company’s stock worth $28,687,000 after purchasing an additional 23,113 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Kura Oncology by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 624,952 shares of the company’s stock worth $12,212,000 after purchasing an additional 14,106 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.